TOX defines the degree of CD8+ T cell dysfunction in distinct phases of chronic HBV infection.

T lymphocytes chronic viral hepatitis hepatitis B immune response

Journal

Gut
ISSN: 1468-3288
Titre abrégé: Gut
Pays: England
ID NLM: 2985108R

Informations de publication

Date de publication:
23 Oct 2020
Historique:
received: 30 06 2020
revised: 22 09 2020
accepted: 24 09 2020
entrez: 24 10 2020
pubmed: 25 10 2020
medline: 25 10 2020
Statut: aheadofprint

Résumé

Chronic hepatitis B virus (HBV) infection is characterised by HBV-specific CD8+ T cell dysfunction that has been linked to Tcell exhaustion, a distinct differentiation programme associated with persisting antigen recognition. Recently, Thymocyte Selection-Associated High Mobility Group Box (TOX) was identified as master regulator of CD8+ T cell exhaustion. Here, we addressed the role of TOX in HBV-specific CD8+ T cell dysfunction associated with different clinical phases of infection. We investigated TOX expression in HBV-specific CD8+ T cells from 53 HLA-A*01:01, HLA-A*11:01 and HLA-A*02:01 positive patients from different HBV infection phases and compared it to hepatitis C virus (HCV)-specific, cytomegalovirus (CMV)-specific, Epstein-Barr virus (EBV)-specific and influenza virus (FLU)-specific CD8+ T cells. Phenotypic and functional analyses of virus-specific CD8+ T cells were performed after peptide-loaded tetramer-enrichment and peptide-specific expansion. Our results show that TOX expression in HBV-specific CD8+ T cells is linked to chronic antigen stimulation, correlates with viral load and is associated with phenotypic and functional characteristics of T-cell exhaustion. In contrast, similar TOX expression in EBV-specific and CMV-specific CD8+ T cells is not linked to T-cell dysfunction suggesting different underlying programmes. TOX expression in HBV-specific CD8+ T cells is also affected by targeted antigens, for example, core versus polymerase. In HBV-specific CD8+ T cells, TOX expression is maintained after spontaneous or therapy-mediated viral control in chronic but not self-limiting acute HBV infection indicating a permanent molecular imprint after chronic but not temporary stimulation. Our data highlight TOX as biomarker specific for dysfunctional virus-specific CD8+ T cells in the context of an actively persisting infection.

Identifiants

pubmed: 33097558
pii: gutjnl-2020-322404
doi: 10.1136/gutjnl-2020-322404
pmc: PMC8292571
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom

Informations de copyright

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Immunity. 2012 Dec 14;37(6):1130-44
pubmed: 23159438
J Clin Invest. 1996 Apr 1;97(7):1655-65
pubmed: 8601631
Hepatology. 2011 May;53(5):1494-503
pubmed: 21360567
Nature. 2019 Jul;571(7764):265-269
pubmed: 31207605
Gut. 2019 May;68(5):905-915
pubmed: 30622109
J Exp Med. 2014 Sep 22;211(10):2047-59
pubmed: 25225458
Gastroenterology. 1999 Dec;117(6):1386-96
pubmed: 10579980
Nat Immunol. 2019 Jul;20(7):890-901
pubmed: 31209400
Science. 2012 Nov 30;338(6111):1220-5
pubmed: 23197535
Gut. 2019 May;68(5):893-904
pubmed: 30580250
Gut. 2019 May;68(5):770-773
pubmed: 30700541
Immunity. 2018 May 15;48(5):1029-1045.e5
pubmed: 29768164
J Clin Invest. 2008 May;118(5):1835-45
pubmed: 18398508
Int J Mol Sci. 2019 Jun 05;20(11):
pubmed: 31195619
Nat Commun. 2017 May 03;8:15050
pubmed: 28466857
J Virol. 2007 Apr;81(8):4215-25
pubmed: 17287266
Immunity. 2016 Aug 16;45(2):415-27
pubmed: 27533016
Nature. 2016 Aug 2;537(7620):412-428
pubmed: 27501245
Gastroenterology. 2010 Feb;138(2):682-93, 693.e1-4
pubmed: 19800335
J Virol. 2003 Jan;77(1):68-76
pubmed: 12477811
Gastroenterology. 2020 Aug;159(2):652-664
pubmed: 32302614
Nature. 2019 Jul;571(7764):211-218
pubmed: 31207603
J Clin Invest. 2018 Feb 1;128(2):668-681
pubmed: 29309050
Gastroenterology. 2012 Oct;143(4):963-73.e9
pubmed: 22796241
J Hepatol. 2014 Dec;61(6):1212-9
pubmed: 25016223
Nature. 2016 Sep 15;537(7620):417-421
pubmed: 27501248
Nat Rev Gastroenterol Hepatol. 2019 Nov;16(11):662-675
pubmed: 31548710
Blood. 2010 May 6;115(18):3718-25
pubmed: 20200354
J Hepatol. 2017 Aug;67(2):370-398
pubmed: 28427875
J Virol. 2004 Jun;78(11):5707-19
pubmed: 15140968
J Virol. 2015 Jan;89(1):25-34
pubmed: 25320295
Nat Med. 2017 Mar;23(3):327-336
pubmed: 28165481
Sci Immunol. 2020 Jul 3;5(49):
pubmed: 32620560

Auteurs

Kathrin Heim (K)

Internal Medicine II, Faculty of Medicine, Freiburg University Hospital, Freiburg, Germany.
Faculty of Biology, University of Freiburg, Freiburg, Germany.

Benedikt Binder (B)

Internal Medicine II, Faculty of Medicine, Freiburg University Hospital, Freiburg, Germany.
Internal Medicine II, Faculty of Medicine, Freiburg University Hospital, Freiburg, Germany.

Dominik Wieland (D)

Internal Medicine II, Faculty of Medicine, Freiburg University Hospital, Freiburg, Germany.

Nina Hensel (N)

Internal Medicine II, Faculty of Medicine, Freiburg University Hospital, Freiburg, Germany.
Faculty of Biology, University of Freiburg, Freiburg, Germany.

Sian Llewellyn-Lacey (S)

Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK.

Emma Gostick (E)

Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK.

David A Price (DA)

Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff, UK.
Systems Immunity Research Institute, Cardiff University School of Medicine, Cardiff, UK.

Florian Emmerich (F)

Institute for Transfusion Medicine and Gene Therapy, Factulty of Medicine, Freiburg University Hospital, Freiburg, Germany.

Hildegard Vingerhoet (H)

Internal Medicine II, Freiburg University Hospital, Freiburg, Germany.

Anke R M Kraft (ARM)

Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Niedersachsen, Germany.
German Centre for Infection Research Association, Braunschweig, Germany.

Markus Cornberg (M)

German Centre for Infection Research Association, Braunschweig, Germany.
Department of Gastroenterology, Hepatology and Endocrinology, Centre for individualised Infection Medicine (CiiM), Hannover Medical School, Hannover, Germany.

Tobias Boettler (T)

Internal Medicine II, Faculty of Medicine, Freiburg University Hospital, Freiburg, Germany.

Christoph Neumann-Haefelin (C)

Internal Medicine II, Faculty of Medicine, Freiburg University Hospital, Freiburg, Germany.

Dietmar Zehn (D)

Division of Animal Physiology and Immunology, School of Life Sciences Weihenstephan, Technical University of Munich, Munich, Germany.

Bertram Bengsch (B)

Internal Medicine II, Faculty of Medicine, Freiburg University Hospital, Freiburg, Germany.
Signalling Research Centres BIOSS and CIBSS, University of Freiburg, Freiburg, Germany.

Maike Hofmann (M)

Internal Medicine II, Faculty of Medicine, Freiburg University Hospital, Freiburg, Germany robert.thimme@uniklinik-freiburg.de Maike.Hofmann@uniklinik-freiburg.de.

Robert Thimme (R)

Internal Medicine II, Faculty of Medicine, Freiburg University Hospital, Freiburg, Germany robert.thimme@uniklinik-freiburg.de Maike.Hofmann@uniklinik-freiburg.de.

Classifications MeSH